Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. T. van Meerten

Publicaties

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma

VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

High frequency of hyperglycaemia observed during CAR T-cell treatment

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

MO-0960 Evaluating semi-automated 18F-FDG PET segmentation methods to predict Large B-cell lymphoma outcomes

Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities

Lees meer

Pers/media

Groningse CAR-T-celtherapie krijgt KWF-subsidie

Hoe een Gronings ziekenhuis het opneemt tegen big pharma

Dit was 2021: Genezen

UMCG gaat zelf medicijn tegen lymfeklierkanker maken

Podcast De Genezers over CAR T-celtherapie

Gronings ziekenhuis gaat prijzig kankermedicijn zelf maken met miljoenensubsidie

€ 30 miljoen subsidie voor UMCG-onderzoek naar veelbelovende kankerbehandeling

Wanneer milieuwetgeving de strijd tegen kanker hindert

Doorbraak in behandeling lymfeklierkanker

Lees meer